drugset / Trial / NCT05603403

Efficacy And Safety Of Probiatop In The Treatment Of Digestive Symptoms

NCT05603403

Phase 4 Completed 150 enrolled Azidus Brasil Farmoquimica S.A. · collab
RandomizedParallel-groupDouble-blindTreatment

Summary

A Multicenter, Randomized, Double-blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Probiatop in the Treatment of Digestive Symptoms. Phase IV. The casuistic presented in this protocol is 150 participants randomized at a 1:1 ratio (75 receiving Probiatop and 75 receiving placebo), balanced by age, sex, prebiotic intake\* and summation of the Gastrointestinal Symptom Rating Scale (GSRS) questions related to the domains of diarrhea (questions 11, 12, and 14), indigestion (questions 6, 7, 8, and 9), and constipation (questions 10, 13, and 15) separated by intensity and frequency. Participants with recurrent digestive symptoms for at least 3 months, with a score of 21 on the sum of questions 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15 of the GSRS (corresponding to the domains diarrhea, indigestion and constipation) will be randomized to Probiatop or placebo.

Timeline

Start
2022-10-20
Primary completion
2023-03-15
Completion
2023-03-15

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Probiotics Other / unclassified 1 g Oral